SB-0110 / Sinopia Biosci - LARVOL DELTA

Sinopia Biosciences Selects Lead Clinical Candidate, Secures Funding to Advance into the Clinic for Parkinson’s Disease (Businesswire) - "Sinopia Biosciences, Inc...announced today that it has selected SB-0110 after extensive preclinical studies as its lead clinical candidate for Parkinson’s disease and levodopa-induced dyskinesia. By successfully meeting this milestone, Sinopia has triggered Phase II funding of its Fast Track Small Business Innovation Research (SBIR) grant for a cumulative funding of $3.3M awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH). Further, Sinopia has been selected to receive $2.0M in funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance SB-0110 into Phase 1 clinical trials."

Financing • CNS Disorders • Parkinson's Disease